Spots Global Cancer Trial Database for oropharynx squamous cell carcinoma
Every month we try and update this database with for oropharynx squamous cell carcinoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Radiotherapy, Carboplatin/Paclitaxel and Nivolumab for High Risk HPV-related Head and Neck Cancer | NCT03829722 | Oropharynx Squa... | Nivolumab Carboplatin Paclitaxel Radiation Thera... | 18 Years - | University of Michigan Rogel Cancer Center | |
| Training Swallowing Initiation During Expiration | NCT05278039 | Head and Neck C... Dysphagia Oropharyngeal D... Oropharynx Squa... | Respiratory-Swa... Swallow Practic... | 18 Years - | Northwestern University | |
| QUantitative Assessment of Swallowing After Radiation (QUASAR) | NCT04359199 | Head and Neck C... Dysphagia Oropharyngeal D... Oropharynx Canc... Oropharynx Squa... | Radiation Thera... Cetuximab Chemotherapy Immunotherapy | 18 Years - | University of California, San Diego | |
| Study Comparing Fibula Free-flap MR With or Without PVP in Patients With OOPC | NCT04725396 | Oropharynx Squa... Oral Cavity Squ... | Mandibular Reco... Conventional Ma... | 18 Years - | UNICANCER | |
| SURVEILLE-HPV: Evaluation of HPV16 Circulating DNA as Biomarker to Detect the Recurrence, in Order to Improve Post Therapeutic Surveillance of HPV16-driven Oropharyngeal Cancers | NCT05582122 | Oropharynx Squa... | HPV16 Ct-DNA do... | 18 Years - | UNICANCER | |
| Adjuvant De-Escalated Radiation + Adjuvant Nivolumab for Intermediate-High Risk P16+ Oropharynx Cancer | NCT03715946 | Carcinoma, Squa... Oropharynx Squa... | Nivolumab Injec... Radiotherapy (R... | 18 Years - | University of Pittsburgh | |
| Study Comparing Fibula Free-flap MR With or Without PVP in Patients With OOPC | NCT04725396 | Oropharynx Squa... Oral Cavity Squ... | Mandibular Reco... Conventional Ma... | 18 Years - | UNICANCER | |
| Detection of Oral and Throat Cancers Using OralViome Cancer Testing System | NCT05451303 | Oral Squamous C... Oropharynx Squa... Premalignant Le... | OralViome Cance... | 18 Years - | Viome | |
| First Line Weekly Chemo/Immunotherapy for Metastatic Head/Neck Squamous Cell Carcinoma Patients | NCT04858269 | Head Neck Cance... Metastatic Squa... Oral Cavity Squ... Oropharynx Squa... Hypopharynx Squ... Larynx Squamous... | Pembrolizumab Carboplatin Paclitaxel | 18 Years - | Wake Forest University Health Sciences | |
| Detection of Oral and Throat Cancers Using OralViome Cancer Testing System | NCT05451303 | Oral Squamous C... Oropharynx Squa... Premalignant Le... | OralViome Cance... | 18 Years - | Viome | |
| Adjuvant De-Escalated Radiation + Adjuvant Nivolumab for Intermediate-High Risk P16+ Oropharynx Cancer | NCT03715946 | Carcinoma, Squa... Oropharynx Squa... | Nivolumab Injec... Radiotherapy (R... | 18 Years - | University of Pittsburgh | |
| Circulating Biomarkers in Oropharyngeal Cancers | NCT05904327 | Oropharynx Squa... Oropharynx Canc... Tonsillar Cance... Base of the Ton... | - | Region Örebro County | ||
| A Study of Concurrent Chemoradiation in Combination With or Without PD1 Inhibitor AB122 Adenosine 2a Receptor / Adenosine 2b Receptor Inhibitor AB928 Therapies in Locally Advanced Head and Neck Cancers | NCT04892875 | Head and Neck C... Squamous Cell C... Oral Cavity Squ... Oral Cavity Can... Oropharynx Canc... Oropharynx Squa... Larynx Cancer Pharynx Cancer Hypopharynx Can... Hypopharynx Squ... | Zimberelimab Etrumadenant Cisplatin Radiation | 18 Years - | Vanderbilt-Ingram Cancer Center | |
| Prospective Observational Study to Validate Circulating HPVDNA and Prognostic Genomic Biomarkers in HPV-associated OPSCC | NCT04564989 | Oropharyngeal S... Carcinoma, Squa... Head and Neck S... Oropharynx Squa... | 18 Years - | UNC Lineberger Comprehensive Cancer Center | ||
| Training Swallowing Initiation During Expiration | NCT05278039 | Head and Neck C... Dysphagia Oropharyngeal D... Oropharynx Squa... | Respiratory-Swa... Swallow Practic... | 18 Years - | Northwestern University | |
| Intensity-Modulated Proton Therapy (IMPT) or TransOral Robotic Surgery (TORS) for the Treatment of Low-Risk Oropharynx Squamous Cell | NCT02663583 | Cancer of the M... Oropharynx Squa... | Symptom Questio... Dysphagia Inven... Activity Bands | 18 Years - | M.D. Anderson Cancer Center | |
| SURVEILLE-HPV: Evaluation of HPV16 Circulating DNA as Biomarker to Detect the Recurrence, in Order to Improve Post Therapeutic Surveillance of HPV16-driven Oropharyngeal Cancers | NCT05582122 | Oropharynx Squa... | HPV16 Ct-DNA do... | 18 Years - | UNICANCER | |
| A Study of Concurrent Chemoradiation in Combination With or Without PD1 Inhibitor AB122 Adenosine 2a Receptor / Adenosine 2b Receptor Inhibitor AB928 Therapies in Locally Advanced Head and Neck Cancers | NCT04892875 | Head and Neck C... Squamous Cell C... Oral Cavity Squ... Oral Cavity Can... Oropharynx Canc... Oropharynx Squa... Larynx Cancer Pharynx Cancer Hypopharynx Can... Hypopharynx Squ... | Zimberelimab Etrumadenant Cisplatin Radiation | 18 Years - | Vanderbilt-Ingram Cancer Center | |
| Quality of Life After Primary TORS vs IMRT for Patients With Early-stage Oropharyngeal Squamous Cell Carcinoma | NCT04124198 | Oropharynx Canc... Oropharynx Squa... Carcinoma, Squa... Carcinoma Oropharyngeal N... Neoplasms, Squa... Neoplasms, Glan... Neoplasms by Hi... Pharyngeal Neop... Otorhinolaryngo... Head and Neck N... Neoplasms by Si... Otorhinolaryngo... Pharyngeal Dise... Papillomavirus ... Virus Diseases DNA Virus Infec... Tumor Virus Inf... Quality of Life | Intensity-Modul... Cisplatin Nimorazole. Transoral Robot... | 18 Years - | Rigshospitalet, Denmark | |
| IRX-2 Regimen and Durvalumab, for Incurable H&N Squamous Cell Carcinoma | NCT03381183 | Squamous Cell C... Squamous Cell C... Metastatic Squa... Oral Cavity Squ... Oropharynx Squa... Paranasal Sinus... Hypopharynx Squ... Larynx Squamous... | Durvalumab IRX-2 Regimen | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Intensity-Modulated Proton Therapy (IMPT) or TransOral Robotic Surgery (TORS) for the Treatment of Low-Risk Oropharynx Squamous Cell | NCT02663583 | Cancer of the M... Oropharynx Squa... | Symptom Questio... Dysphagia Inven... Activity Bands | 18 Years - | M.D. Anderson Cancer Center | |
| Saliva-based Detection of CD44 | NCT03148665 | Oral Cavity Squ... Oropharynx Squa... Squamous Cell C... Squamous Cell C... | OncAlert | 18 Years - | University of California, San Diego | |
| Training Swallowing Initiation During Expiration | NCT05278039 | Head and Neck C... Dysphagia Oropharyngeal D... Oropharynx Squa... | Respiratory-Swa... Swallow Practic... | 18 Years - | Northwestern University | |
| First Line Weekly Chemo/Immunotherapy for Metastatic Head/Neck Squamous Cell Carcinoma Patients | NCT04858269 | Head Neck Cance... Metastatic Squa... Oral Cavity Squ... Oropharynx Squa... Hypopharynx Squ... Larynx Squamous... | Pembrolizumab Carboplatin Paclitaxel | 18 Years - | Wake Forest University Health Sciences | |
| Quality of Life After Primary TORS vs IMRT for Patients With Early-stage Oropharyngeal Squamous Cell Carcinoma | NCT04124198 | Oropharynx Canc... Oropharynx Squa... Carcinoma, Squa... Carcinoma Oropharyngeal N... Neoplasms, Squa... Neoplasms, Glan... Neoplasms by Hi... Pharyngeal Neop... Otorhinolaryngo... Head and Neck N... Neoplasms by Si... Otorhinolaryngo... Pharyngeal Dise... Papillomavirus ... Virus Diseases DNA Virus Infec... Tumor Virus Inf... Quality of Life | Intensity-Modul... Cisplatin Nimorazole. Transoral Robot... | 18 Years - | Rigshospitalet, Denmark | |
| Prospective Observational Study to Validate Circulating HPVDNA and Prognostic Genomic Biomarkers in HPV-associated OPSCC | NCT04564989 | Oropharyngeal S... Carcinoma, Squa... Head and Neck S... Oropharynx Squa... | 18 Years - | UNC Lineberger Comprehensive Cancer Center | ||
| Adjuvant De-Escalated Radiation + Adjuvant Nivolumab for Intermediate-High Risk P16+ Oropharynx Cancer | NCT03715946 | Carcinoma, Squa... Oropharynx Squa... | Nivolumab Injec... Radiotherapy (R... | 18 Years - | University of Pittsburgh | |
| IRX-2 Regimen and Durvalumab, for Incurable H&N Squamous Cell Carcinoma | NCT03381183 | Squamous Cell C... Squamous Cell C... Metastatic Squa... Oral Cavity Squ... Oropharynx Squa... Paranasal Sinus... Hypopharynx Squ... Larynx Squamous... | Durvalumab IRX-2 Regimen | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Monitoring and Early Response Evaluation Using HPV DNA - A Study on Patients With HPV-positive Throat Cancer (MER-HPV) | NCT05649865 | Oropharynx Squa... | Blood sample | 18 Years - | Region Skane | |
| SURVEILLE-HPV: Evaluation of HPV16 Circulating DNA as Biomarker to Detect the Recurrence, in Order to Improve Post Therapeutic Surveillance of HPV16-driven Oropharyngeal Cancers | NCT05582122 | Oropharynx Squa... | HPV16 Ct-DNA do... | 18 Years - | UNICANCER | |
| A Trial To Find Out If Vidutolimod Together With Cemiplimab Is Safe And If It Works In Adult Participants With Advanced Cancer Or Metastatic Cancer | NCT04916002 | Merkel Cell Car... Cutaneous Squam... Basal Cell Carc... Triple Negative... Non-Small Cell ... Oropharynx Squa... | vidutolimod cemiplimab | 18 Years - | Regeneron Pharmaceuticals | |
| First Line Weekly Chemo/Immunotherapy for Metastatic Head/Neck Squamous Cell Carcinoma Patients | NCT04858269 | Head Neck Cance... Metastatic Squa... Oral Cavity Squ... Oropharynx Squa... Hypopharynx Squ... Larynx Squamous... | Pembrolizumab Carboplatin Paclitaxel | 18 Years - | Wake Forest University Health Sciences | |
| Radiotherapy, Carboplatin/Paclitaxel and Nivolumab for High Risk HPV-related Head and Neck Cancer | NCT03829722 | Oropharynx Squa... | Nivolumab Carboplatin Paclitaxel Radiation Thera... | 18 Years - | University of Michigan Rogel Cancer Center | |
| A Study of Concurrent Chemoradiation in Combination With or Without PD1 Inhibitor AB122 Adenosine 2a Receptor / Adenosine 2b Receptor Inhibitor AB928 Therapies in Locally Advanced Head and Neck Cancers | NCT04892875 | Head and Neck C... Squamous Cell C... Oral Cavity Squ... Oral Cavity Can... Oropharynx Canc... Oropharynx Squa... Larynx Cancer Pharynx Cancer Hypopharynx Can... Hypopharynx Squ... | Zimberelimab Etrumadenant Cisplatin Radiation | 18 Years - | Vanderbilt-Ingram Cancer Center |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
